Plasma Cell Myeloma Refractory: Clinical Trials

2 recruiting, 1 active not recruiting. 2 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	2	Recruiting 2
Phase 2	2	Active not recruiting 1, Recruiting 1

Follow Plasma Cell Myeloma Refractory: new trials by email Literature Review of Plasma Cell Myeloma Refractory trials Research Report on Plasma Cell Myeloma Refractory

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma Isatuximab SC-OBDS, Montelukast, Dexamethasone - Plasma Cell Myeloma Refractory	Phase 2	Active not recruiting	Sanofi	64	2025-03-17	2026-10-26
A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma SAR446523 - Plasma Cell Myeloma Refractory	Phase 1	Recruiting	Sanofi	87	2024-10-30	2026-03-25
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol Isatuximab, Dexamethasone, Pomalidomide - Plasma Cell Myeloma Refractory	Phase 1 / Phase 2	Recruiting	Sanofi	258	2021-01-25	2026-10-13

Interventions

Dexamethasone (2)  ·  isatuximab (2)  ·  ALX148 (1)  ·  Acetaminophen (1)  ·  Diphenhydramine (1)  ·  Methylprednisolone (1)  ·  belantamab mafodotin (1)  ·  belumosudil (1)  ·  carfilzomib (1)  ·  montelukast (1)  ·  pomalidomide (1)

Sponsors

Sanofi (3)

Countries

United States (3)  ·  Australia (2)  ·  France (2)  ·  Israel (2)  ·  Italy (2)  ·  Canada (1)  ·  Germany (1)  ·  Greece (1)  ·  Norway (1)  ·  South Korea (1)  ·  Spain (1)